Product Description: Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM[1]. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface[3].
Formula: C29H42F3N9O9
Citations: Acs Biomater Sci Eng. 2023 Apr 24./ACS Appl Mater Interfaces. 2019 Jul 31;11(30):26648-26663. /Acta Biomater. 2021 Mar 9;S1742-7061(21)00152-5./Adv Healthc Mater. 2021 May 29;e2100304./Bioact Mater. 2021 Jan 7;6(7):2039-2057./Biochem Biophys Res Commun. 2023 May 23./Drug Deliv Transl Res. 2024 Mar 18./Engineering. 8 October 2020./Heliyon. 2024 July 02./Mater Today Nano. 2023 Nov 10, 100432./Mol Ther Nucleic Acids. 2021 Jan 9;23:797-810.
References: [1]Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95./[2]Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.
CAS Number: 500577-51-5
Molecular Weight: 717.69
Compound Purity: 99.82
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)/H2O : 33.33 mg/mL (ultrasonic)
Target: Integrin
English
Deutsch
